Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study
This study demonstrated comparable efficacy and improved safety of DOACs over warfarin in a predominantly lower-risk APS population. Caution is advised, particularly in APS patients with triple-positive antiphospholipid antibodies or history of arterial thrombosis.
Authors
- Ali Eshaghpour (ORCID: https://orcid.org/0000-0002-7827-5827)
- Mohamed Amgad (ORCID: https://orcid.org/0000-0001-7599-6162)
- Maha AT Elsebaie (ORCID: https://orcid.org/0000-0001-8953-4030)
- Zoe Alexandra Wickham
- Stephanie Debragga
- Manila Gaddh (ORCID: https://orcid.org/0000-0002-0817-9848)
- Stacey A. Fedewa (ORCID: https://orcid.org/0000-0002-3624-6382)
- Jane Jungyoon Park
- Juan Li (ORCID: https://orcid.org/0000-0001-7070-1222)
- Allen Li (ORCID: https://orcid.org/0000-0001-6615-7295)
- Mark Crowther (ORCID: https://orcid.org/0009-0004-6072-7735)
Institutions
- Northwestern University (US)
- American Cancer Society (US)
- Emory University (US)
- University of Ottawa (CA)
- Ottawa Hospital (CA)
- University of Chicago Medical Center (US)
- Ottawa Hospital Research Institute (CA)
- Imperial College London (GB)
- McMaster University (CA)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1016/j.rpth.2025.102856
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00